The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals.
Biotechnology-derived pharmaceuticals, or biopharmaceuticals, represent a special class of complex, high molecular weight products, such as monoclonal antibodies, recombinant proteins, and nucleic acids. With these compounds, it is not appropriate to follow conventional safety testing programs, and the preclinical "package" for each biopharmaceutical needs to be individually designed. In addition to standard histopathology, the use of molecular pathology techniques is often required either in conventional animal studies or in in vitro tests. In this review, the safety evaluation of biopharmaceuticals is discussed from the perspective of the toxicologic pathologist, and appropriate examples are given of the use of molecular pathology procedures. Examples include the use of in situ hybridization to localize gene therapy vectors, the assessment of vector integration into genomic DNA by the polymerase chain reaction (PCR), and the use of immunohistochemistry to evaluate the potential cross-reactivity of monoclonal antibodies. In situ PCR techniques may allow for confirmation of the germ cell localization of nucleic acids and may therefore facilitate the risk assessment of germline transmission. Increased involvement with biopharmaceuticals will present challenging opportunities for the toxicologic pathologist and will allow for much greater use of molecular techniques, which have a critical role in the preclinical development of these compounds.
Pilling
A M
AM
Medicines Safety Evaluation Division, Glaxo Wellcome Research and Development Ltd., Ware, Hertfordshire, United Kingdom. amp1069@ggr.co.uk
D000818:Animals; D000911:Antibodies, Monoclonal; D001688:Biological Products / Q000009:adverse effects / Q000592:standards*; D001709:Biotechnology / Q000592:standards*; D004340:Drug Contamination / Q000517:prevention & control; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000592:standards*; D015316:Genetic Therapy / Q000009:adverse effects / Q000592:standards; D006801:Humans; D051379:Mice; D016376:Oligonucleotides, Antisense / Q000009:adverse effects / Q000592:standards; D016337:RNA, Catalytic / Q000009:adverse effects / Q000592:standards; D011994:Recombinant Proteins / Q000009:adverse effects / Q000592:standards; D014116:Toxicology / Q000592:standards*
D000911:Antibodies, Monoclonal; D001688:Biological Products; D016376:Oligonucleotides, Antisense; D016337:RNA, Catalytic; D011994:Recombinant Proteins